Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5
PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc. PMVP | 0.00 |
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:
PMVP) with a Outperform and lowers the price target from $6 to $5.
